| Literature DB >> 34125424 |
Agam Vora1, Alberta Di Pasquale2, Shafi Kolhapure3, Ashish Agrawal4.
Abstract
Over the last 50 years, the Indian population aged 50 years and above (older adults) has quadrupled and is expected to comprise 404 million people in 2036, representing 27% of the country's projected population. Consequently, the contribution of chronic disease to older adults' total burden of diseases in India is likely to escalate. Disease burden is notably amplified by immunosenescence, a deterioration of the immune system that develops with age, leading to increasing susceptibility to infectious diseases and other comorbidities. Older adults with infectious diseases have a higher incidence and likelihood of life-threatening comorbidities such as coronary artery disease, arrhythmia, stroke, myocardial infarction, hypertension, dyslipidemia, and diabetes mellitus. Therefore, immunization of older adults through vaccination might greatly reduce the burden imposed by vaccine preventable infectious diseases in this population. Here, we review evidence relevant to the disease burden among adults aged ≥ 50 years in India, and existing vaccination recommendations. Furthermore, we suggest a set of routine vaccinations for healthy older adults in India. There is a clear mandate to recognize the contributions of older adults to society and embrace strategies promoting healthy aging, which is described by the World Health Organization as the process of developing and maintaining functional ability and well-being in older age. Increasing vaccination awareness and coverage among older adults is an important step in that direction for India.Entities:
Year: 2021 PMID: 34125424 PMCID: PMC8200323 DOI: 10.1007/s40266-021-00864-4
Source DB: PubMed Journal: Drugs Aging ISSN: 1170-229X Impact factor: 3.923
Fig. 1Plain language summary
Fig. 2Projections of population distribution by age group in India based on the 2011 Census data; years 2011, 2016, 2021, 2026, 2031, and 2036. Created from: Census of India 2011. Population projections for India and States 2011–36. Report of the Technical Group on Population Projections, November 2019. National Commission on Population. Ministry of Health and Family Welfare, Government of India [3]
Fig. 3Biological aging and its impact on the functionality of organs and the immune system. Created from [42]. NK natural killer
Recommendations for routine vaccinations of healthy older adults without risk factors as per age group
| Disease | Age (years) | USA [ | Europe | Indian Geriatric Society [ | Author’s proposal | |
|---|---|---|---|---|---|---|
| UK [ | Germany [ | |||||
| Diptheria, tetanus, pertussis | ≥ 50–64 | 1 Tdap + Td/Tdap booster every 10 years | – | 1 Tdap booster every 10 years (≥ 60 years) | 1 Tdap + Td booster every 10 years | 1 Tdap + Td/Tdap booster every 10 years |
| ≥ 65 | – | |||||
| Measles, mumps, rubellaf | ≥ 50–59 | 1–2 doses (if born in 1957 or later) | – | – | – | 1–2 doses |
| ≥ 60 | – | – | – | |||
| Varicellaf | ≥ 50–64 | 2 doses | – | – | – | 1–2 doses |
| ≥ 65 | – | – | ||||
| Influenza | ≥ 50–64 | 1 dose annually | – | 1 dose annually (≥ 60 years) | 1 dose annually | 1 dose annually |
| ≥ 65 | 1 dose annually | |||||
| Herpes zoster | ≥ 50–64 | 1a (≥ 60 years) or 2b (≥ 50 years) doses | – | 1b dose (≥ 60 years) | – | 1a or 2b doses |
| ≥ 65 | 1 dose (≥ 70 years) | |||||
| Pneumococcal disease | ≥ 50–64 | – | – | 1c dose (≥ 60 years) | 1 dosee or c | – |
| ≥ 65 | 1c dose | 1c dose | 1 dosee or c | 1 dosee or c | ||
| Hepatitis A | ≥ 50–64 | 2 or 3 dosesd | – | – | – | 1 or 2 dosesd |
| ≥ 65 | – | – | ||||
| Hepatitis B | ≥ 50–64 | 2 or 3 dosesd | – | – | – | 2 or 3 dosesd |
| 7 ≥ 65 | – | – | ||||
| Meningococcal A, C, W, Y | ≥ 50–64 | 1 dosed | – | – | – | 1 dose |
| ≥ 65 | – | – | ||||
| Meningococcal B | Recommendations to specific populations at risk and based on local recommendations | |||||
| COVID-19 | 1 or 2 doses depending on vaccine and local recommendations | |||||
Td tetanus-diphtheria vaccine, Tdap tetanus-diphtheria-acellular pertussis vaccine
aLive vaccine
bInactivated vaccine
cPolysaccharide vaccine
dDepending on vaccine and/or local recommendations
e13-valent conjugate vaccine
fWithout known history of vaccination or disease
Fig. 4Barriers and opportunities regarding older adults’ vaccination. Created based on [8, 23, 41, 64, 67]. HCP healthcare professionals
| Over the last 50 years, the population of India aged ≥ 50 years (older adults) has quadrupled and is expected to increase further. |
| People aged ≥ 50 years are prone to infectious diseases due to immunosenescence and other declining physiological functions. |
| Increasing vaccination awareness and coverage among older adults in India is an important step towards healthy aging. |